Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529294 · ClinicalTrials.gov registry record · Phase 1
Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01529294 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT01529294, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone in subjects with mild or moderate hepatic impairment comparatively to healthy matched subjects
Interventions
- DRUG Iloperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529294
The ClinicalTrials.gov registry entry for NCT01529294 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iloperidone is the first listed.
NCT01529294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529294 about?
NCT01529294 is a clinical study titled "Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers". This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone in subjects with mild or moderate hepatic impairment comparatively to healthy matched subjects
What is the current status of trial NCT01529294?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2010-08. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01529294?
The interventions under investigation include: Iloperidone (DRUG).
Who is sponsoring clinical trial NCT01529294?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.